

50/60/10
6/28UTILITY PATENT APPLICATION
TRANSMITTAL

(For new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

P50203-1D1C1


First Named Inventor

Jerry Ler y Adams

"EXPRESS MAIL" MAILING LABEL NUMBER **EV332944614US**

DATE OF DEPOSIT: 09 July 2003

I hereby certify that this paper or fee and the papers indicated as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to:
COMMISSIONER FOR PATENTS, MAIL STOP: PATENT APPLICATION, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

NAME OF PERSON MAILING PAPER OR FEE
(TYPE OR PRINT) **STEVEN OLSZEWSKI**SIGNATURE 19704 U.S. PTO
10/616333
07/09/03

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. 19-2570
 General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3))
(Submit an original, and a duplicate for fee processing)

The Title of the Invention:

Oxazoles for Treating Cytokine Mediated Diseases

2. The total fee is calculated as shown below:
 Basic Filing fee \$750.00
 Total Claims 34 - 20 = 0 x \$18 \$252.00
 Independent Claims 2 -3 = 0 x \$84 \$ 0.00
 Multiple Dependent Claim present. \$280
TOTAL FILING FEE \$1,002.00
 Cancel in this application original claims to of the prior application before calculating the filing fee.
 Charge **\$1,002.00** to the above indicated Deposit Account.

Nucleotide and/or Amino Acid Sequence Submission
 a. Computer Readable Copy
 b. Paper Copy (identical to computer copy)
 c. Statement verifying identity of above copies
 d. Use the identical computer-readable form filed in Application No. _____, filed _____ as the computer-readable form for the instant application. (37 CFR 1.821(e))

3a. Specification excluding Drawings [Total Pages] 42
 3b. Abstract on a separate sheet [Total Pages] 1
 4. Drawing(s) (35 USC 113) [Total Sheets] _____

5. Declaration and Power of Attorney [Total Pages] 3
 a. Newly executed (original or copy)
 b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17a completed)
 c. Unsigned Declaration
[Note Box 6 below]
 i. DELETION OF INVENTOR(S)
 Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

ACCOMPANYING APPLICATION PARTS

a. Information Disclosure Statement (IDS)
 b. PTO-1449
 c. Copies of all IDS Citations


Assignment Papers (cover sheet & document(s))

Prior Application is Assigned to:

SmithKline Beecham Corporation*(for continuation/divisional with Box 17a completed)*12. Preliminary Amendment [Total Pages] 1013. Return Receipt Postcard (MPEP 503)
*(Should be specifically itemized)*14. Certified Copy of Priority Document(s)
*(if foreign priority is claimed)*15. Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. 09/769,096 filed January 25, 2001. A PTO-1449 listing the references is enclosed.16. Other: _____6. Incorporation By Reference *(useable if Box 5b is checked)*

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

17.	<input checked="" type="checkbox"/> Priority Information, check appropriate box and supply the requisite information		
a.	The accompanying application is a <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: <u>09/769,096</u> filed <u>January 25, 2001</u> .		
b.	<input type="checkbox"/> Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No. <u> </u> filed <u> </u>		
c.	<input checked="" type="checkbox"/> Please amend the specification by inserting before the first line the sentence: (37 CFR 1.78) This is a continuation of application Serial No. <u>09/769,096</u> filed <u>January 25, 2001</u> which is a divisional of USSN <u>09/467,164</u> (US Patent <u>6,288,062</u>), filed <u>20 December 1999</u> , which is a continuation of USSN <u>08/640,966</u> filed <u>May 8, 1996</u> , (abandoned), which is the §371 national stage entry of PCT/US94/13067, filed <u>November 8, 1994</u> (abandoned) which is a continuation in part of USSN <u>08/148,705</u> filed <u>November 8, 1993</u> (abandoned).		

Correspondence Address:	GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939	Telephone: (610) 270-5017	Fax: (610) 270-5090	Signature Name Dara L. Dinner	Respectfully Submitted,  Dara L. Dinner
Registration No.					33,680